Managing Infection in Cancer Patients and Other Immunocompromised Children

REFERENCES

1. ↵
   1. Hübel K,
   2. Hegener K,
   3. Schnell R,
   4. et al.

   (2, 1999) Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 78(2):73–77, pmid:10089021.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Viscoli C,
   2. Varnier O,
   3. Machetti M

   (4 1, 2005) Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 40(Suppl 4):S240–S245, pmid:15768329.

   OpenUrlCrossRefPubMed
3. ↵
   1. Klastersky J,
   2. Paesmans M,
   3. Rubenstein EB,
   4. et al.

   (8, 2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051, pmid:10944139.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. Kuehnert MJ,
   2. Roth VR,
   3. Haley NR,
   4. et al.

   (12, 2001) Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 41(12):1493–1499, pmid:11778062.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Fishman JA

   (12 20, 2007) Infection in solid-organ transplant recipients. N Engl J Med 357(25):2601–2614, pmid:18094380.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Bonilla FA,
   2. Bernstein IL,
   3. Khan DA,
   4. et al.

   (5, 2005) American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94((5 Suppl 1)):S1–S63, pmid:15945566, Erratum in: Ann Allergy Asthma Immunol. 2006 Mar;96(3):504.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Sievers EL,
   2. Dale DC

   (6, 1996) Non-malignant neutropenia. Blood Rev 10(2):95–100, pmid:8813341.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Dale DC,
   2. Liles WC,
   3. Price TH

   (9, 1997) Renewed interest in granulocyte transfusion therapy. Br J Haematol 98(3):497–501, pmid:9332301.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Rolston KV

   (4 1, 2005) Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40(Suppl 4):S246–S252, pmid:15768330.

   OpenUrlCrossRefPubMed
10. ↵
    1. Freifeld AG,
    2. Bow EJ,
    3. Sepkowitz KA,
    4. et al.

    (2 15, 2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431, pmid:21205990, Epub 2011 Jan 4.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Koh A,
    2. Pizzo PA

    (2002) Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia. Cancer Invest 20(3):420–433, pmid:12025236.

    OpenUrlPubMed
12. ↵
    1. Klastersky J,
    2. Paesmans M,
    3. Georgala A,
    4. et al.

    (9 1, 2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24(25):4129–4134, pmid:16943529.

    OpenUrlAbstract/FREE Full Text
13. ↵
    1. Steele RW,
    2. Suttle DE,
    3. LeMaster PC,
    4. Patterson FD,
    5. Canales L

    (11, 1976) Screening for cell-mediated immunity in children. Am J Dis Child 130(11):1218–1221, pmid:984003.

    OpenUrlCrossRefPubMed